References
- 1. Gomollon F, Dignass A, Annese V, Tilg H, Van Assche G, Lindsay JO, et al. 3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn’s Disease 2016: Part 1: Diagnosis and Medical Management. J Crohns Colitis. 2017;11(1):3-25.10.1093/ecco-jcc/jjw168
- 2. Krstic M, Tarabar D, Bojic D, Nagorni A, Hadnadjev L, Dugalic P, et al. P421 Epidemiological study of occurrence, clinical course and treatment options of IBD in Serbia. Results of ESCApe study. Journal of Crohn’s and Colitis. 2012;6:S177.10.1016/S1873-9946(12)60440-1
- 3. Kurti Z, Vegh Z, Golovics PA, Fadgyas-Freyler P, Gecse KB, Gonczi L, et al. Nationwide prevalence and drug treatment practices of inflammatory bowel diseases in Hungary: A population-based study based on the National Health Insurance Fund database. Dig Liver Dis. 2016;48(11):1302-7.10.1016/j.dld.2016.07.012
- 4. Williams C, Panaccione R, Ghosh S, Rioux K. Optimizing clinical use of mesalazine (5-aminosalicylic acid) in inflammatory bowel disease. Therapeutic advances in gastroenterology. 2011;4(4):237-48.10.1177/1756283X11405250
- 5. Dignass A, Lindsay JO, Sturm A, Windsor A, Colombel J-F, Allez M, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management. Journal of Crohn’s and Colitis. 2012;6(10):991-1030.10.1016/j.crohns.2012.09.002
- 6. Rencz F, Pentek M, Bortlik M, Zagorowicz E, Hlavaty T, Sliwczynski A, et al. Biological therapy in inflammatory bowel diseases: access in Central and Eastern Europe. World J Gastroenterol. 2015;21(6):1728-37.10.3748/wjg.v21.i6.1728